NeoDynamics participates in investor meetings during the IPO
CEO Anna Eriksrud and CFO Jörgen Vrenning will present the company and its plans for the future. The investor meetings are free of charge to attend and light refreshments will be served. Please see below for more information concerning the investor meetings and registration to the events.
Investor meetings during the IPO, November 2018
| Date and time | Event | Place | Registration |
| November 7,11:00 – 18:00 | Sedermeradagen Stockholm | Waterfront Congress Center, Nils Ericsons Plan 4,Stockholm | Registration is made at www.sedermera.se |
| November 10, 11:30 – 17:00 | Moneypenny Medlemskonference | Metropol, Kronprinsesse Sofies Vej 35,Copenhagen | Registration is made at https://mymoneyinvest.dk/ |
| November 12, 08:00 - 21:00 | Stora Aktiedagen Göteborg | Svenska Mässan, Mässans Gata 8,Gothenburg | Registration is made at www.aktiespararna.se |
Financial advisor
Sedermera Fondkommission is the financial advisor to NeoDynamics in connection with the issue of units and the planned listing on Spotlight Stock Market. Nordnet Bank AB is acting as Selling Agent in the issue of units.
For further information about the IPO and the planned listing, please contact:
Sedermera Fondkommission
Telephone: +46 (0) 40-615 14 10
E-mail: info@sedermera.se
For further information about NeoDynamics, please contact:
Anna Eriksrud, CEO NeoDynamics AB (publ)
Telephone: +46 8 522 79 667
E-mail: anna.eriksrud@neodynamics.se
About NeoDynamics
Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives precision and control. In close collaboration with leading clinicians, we have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.
Micropulse technology
The micropulse technology is based on a pneumatic insertion mechanism that enables precise and user controlled needle insertion regardless of tissue characteristics. Stepwise needle insertion without noticeable deformation or displacement of surrounding tissue is achieved and visualized under ultrasound.
NeoNavia®
NeoNavia biopsy system is composed of a base unit and a biopsy device, and is operated together with ultrasound imaging guidance. The base unit supplies the biopsy device with power and controls the operation during the biopsy procedure. The current sampling needle is designed to facilitate maximum sampling yield with minimal trauma. This makes the NeoNavia system particularly well suited for ensuring safe and precise sampling of technically challenging lesions. These might be lesions difficult to reach or target, lesions near delicate anatomical structures, and lesions that are easily displaced by the biopsy needle tip, resulting in the collection of non-representative samples.
Currently NeoNavia exists in a CE-marked study version and since late 2016 it has been tested by leading specialists at some 15 cancer centers in Europe, evaluating both the micropulse technology and FlexiPulse needle design in order to demonstrate its strengths. More than 300 patients have undergone breast and axillary lymph node biopsies with this new micropulse technology and a clinical study is currently ongoing in Germany to further establish the technology. The study version has been vital for the development of the enhanced NeoNavia biopsy system planned for commercial launch late 2019.
